CVS: Raised earnings outlook and planned H1 2028 separation mark a position of strength

What happened

CVS reported third-quarter adjusted earnings per share (EPS), a measure of profit per share excluding certain items, of $2.09, up more than 30% year over year. It raised its 2026 adjusted EPS outlook to at least $8.20 and plans to separate into two businesses in the first half of 2028.

Confirmed

Global impact / market context

Higher earnings guidance signals that CVS expects stronger adjusted profit per share in 2026, while the planned split would separate its integrated healthcare solutions business from CVS Pharmacy. The change could alter how investors assess each business and where CVS directs resources, though no split terms are given.

Analyst inference

The reported earnings growth and raised outlook are current performance signals; the separation is a future plan, not a completed transaction. CVS also expects 2027 adjusted EPS of at least $8.65, but the article gives no details on costs, financing, or how profit would be divided after the split.

Analyst inference

What to watch

1. Watch whether CVS meets its 2026 adjusted EPS outlook of at least $8.20; falling short could weaken the earnings case supporting its planned separation. Analyst inference
2. Look for details on the planned first-half 2028 separation, including timing and how the integrated healthcare solutions business and CVS Pharmacy will operate as separate companies. Analyst inference
3. Track whether CVS confirms its 2027 adjusted EPS expectation of at least $8.65 and explains how that forecast relates to the two planned businesses. Analyst inference

Evidence

• Original source link unavailable